Spectros Corporation protects LED spectroscopy technology against alleged infringement

Date Announced: 08 May 2009

PORTOLA VALLEY, Calif. -- Spectros Corporation filed in Federal District Court today against Thermo Fisher Scientific (NYSE: TMO), alleging infringement of Spectros' spectroscopy patent family by TMO's Nanodrop 3300 product.

Spectros invented and commercialized solid-state, broadband, integrated spectroscopy light sources based on white LEDs, and incorporated these into its flagship T-Stat product, replacing hot light bulbs with cool illuminator sources.

The Nanodrop 3300, introduced to market after T-Stat, also incorporates a white LED for spectroscopy. Thermo Fisher promotes this feature as "unconventional," yet TMO holds no published or issued patents covering this approach. Spectros previously approached TMO regarding specific infringed claims on US Patent no. 6,711,426, without success.

"We are surprised that Thermo Fisher Scientific has continued to market devices incorporating our novel and proprietary technology. We trust that, over time, TMO will appreciate the validity and value of the broad, early optical biotechnology intellectual property portfolio held by Spectros," notes David Benaron, CEO.

Spectros and its affiliates have over 80 issued and pending patents in the U.S., Europe, and Japan, forming one of the largest biophotonics intellectual property collections. Spectros' core patents cover optical spectroscopy, fluorimetry, and imaging for use in blood analysis, contrast-targeted cancer surgery, lab-on-chip systems, and benchtop life-sciences equipment. Red Herring reviewed Spectros in a recent market report in which the journal predicted the total market for optical products in optical molecular detection, imaging, and treatment guidance will grow to $12 billion annually over the next five years.

ABOUT SPECTROS:
Spectros markets advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's lead T-Stat product became the first FDA-approved medical device for the detection of ischemia, an insufficient blood flow to tissue. Spectros is developing follow-on molecular diagnostic tools for breast and prostate cancer currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern.

ABOUT THERMO FISHER SCIENTIFIC, INC. (NYSE: TMO):
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics.

Contact
Ms. Elizabeth van Thillo, Marketing Spectros Corporation 650/529.2865

E-mail:info@spectros.com

Web Site:www.spectros.com

More in Company Newsfeed